Symbols / TNXP Stock $15.00 +0.27%

Asset: Stock

Tonix Pharmaceuticals Holding Corp., a fully integrated biopharmaceutical company, develops and commercializes therapies for central nervous system (CNS) disorders, immunology and immuno-oncology, infectious diseases, and rare diseases in the United States. The company offers TONMYA, a cyclobenzaprine HCl sublingual tablet for the treatment of fibromyalgia. It also markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults. In addition, the company develops TNX-102 SL, a cyclobenzaprine HCl sublingual tablet for the treatment of major depressive disorder and acute stress reaction/acute stress disorder; TNX-1300, a double-mutant cocaine esterase for the treatment of cocaine intoxication; TNX-1500, an Fc-modified humanized monoclonal antibody to prevent kidney transplant rejection, as well as to treat autoimmune conditions; TNX-4800, a humanized monoclonal antibody for the seasonal prevention of Lyme disease; and TNX-2900, an intranasal oxytocin potentiated with magnesium for the treatment of Prader-Willi syndrome. Further, it is developing TNX-1900, an intranasal potentiated oxytocin for the treatment of binge eating disorder, adolescent obesity, and bone health in pediatric autism, and arginine-vasopressin deficiency; TNX-801, a live horsepox vaccine for the prevention of smallpox and mpox; TNX-4200, a small molecule broad-spectrum antiviral agent targeting CD45 for the treatment or prevention of viral disease; TNX-4900, a highly selective small-molecule Sigma-1 receptor antagonist for neuropathic pain; TNX-1700, a recombinant Trefoil Factor Family 2 fusion protein for the treatment of gastric and colorectal cancers; and TNX-1800 and TNX-1850, live modified horsepox vaccines for the prevention of COVID. Tonix Pharmaceuticals Holding Corp. was founded in 2007 and is based in Berkeley Heights, New Jersey.

Price estimates from analyst targets and simple models.

Latest analyst rating changes

• Cancer research: Tonix spotlights immuno-oncology work at AACR 2026 - Stock Titan ue, 17 Mar 2026 20
• Noble Financial Has Optimistic Outlook of TNXP Q1 Earnings - MarketBeat Wed, 18 Mar 2026 11
• TNXP stock rises premarket: Investors cheer early traction for fibromyalgia drug despite weak Q4 print - MSN Fri, 13 Mar 2026 14
• Auditor change at Tonix (NASDAQ: TNXP) after going concern warning - Stock Titan Wed, 18 Mar 2026 10
• TONIX PHARMACEUTICALS HOLDIN (TNXP) Fundamental Analysis & Valuation - ChartMill Fri, 13 Mar 2026 07
• Understanding Momentum Shifts in (TNXP) - Stock Traders Daily Sat, 14 Mar 2026 11
• Tonix Q4: Revenue Beat, EPS Miss, Early Signs Of Tonmya Momentum (NASDAQ:TNXP) - Seeking Alpha ue, 17 Mar 2026 14
• Tonix Pharmaceuticals reports $13.1M product revenue, $124.0M net loss for FY2025 - TradingView Fri, 13 Mar 2026 10
• Tonix Pharmaceuticals Holding (TNXP) Q4 Loss Deepens Community Concerns Despite Revenue Progress - simplywall.st Fri, 13 Mar 2026 22
• New fibromyalgia treatment Tonmya shows gains in patient outcomes poster - Stock Titan ue, 03 Mar 2026 08
• Tonix Eyes TNX‑102 SL Expansion, But We Need To See Tonmya Revenue First (NASDAQ:TNXP) - Seeking Alpha ue, 20 Jan 2026 08
• Biotech Tonix joins Nasdaq’s top tier, which may boost visibility - Stock Titan ue, 03 Mar 2026 08
• Tonix Pharmaceuticals (TNXP) CMO granted two new stock option awards - Stock Titan hu, 26 Feb 2026 08
• First new fibromyalgia drug in 15 years sees 4,200 Tonmya prescriptions - Stock Titan hu, 12 Mar 2026 21
• After 15-year gap, new non-opioid fibromyalgia drug improves pain and sleep - Stock Titan Fri, 30 Jan 2026 08

• Income Statement
• Balance Sheet
• Cash Flow

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

• 8-K2026-03-18 View
• 8-K2026-03-13 View
• 10-K2026-03-12 View
• 8-K2026-03-10 View
• 8-K2026-03-03 View
• 42026-02-26 View
• 42026-02-26 View
• 42026-02-26 View
• 42026-02-26 View
• 42026-02-26 View
• 8-K2026-02-03 View
• 8-K2025-12-29 View
• 8-K2025-12-29 View
• 8-K2025-12-16 View
• 8-K2025-12-09 View